BCRX

BioCryst Pharmaceuticals, Inc.

Contracts

Total Value

Stock Metrics

14.8%

Short % Float

12.4d to cover · Moderate squeeze

1.0%

Inst % Float

10 holders · 2026-06-30

Blackrock Inc.

Top Holder

9.3% of float

220.9M sh

Public Float

26/100

Dilution Score

Medium

15 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

26/100

MEDIUM

Inst: 1.03% · Top: Blackrock Inc.

Biotech Analytics

Rare Disease

56.47

Squeeze risk: MODERATE

Insider Buying0

Publications100

Dilution Risk26

Clinical Trials100

Short Interest50